Given the fact that CDK4/6 kinase inhibitors are already used in clinics but show a number of limitations when treating certain types of cancers and the appearance of resistance mechanisms to CDK4/6 kinase inhibitors, new strategies to target CDK6 are needed.53 The gene discussed is CDK6; the disease is cancer.